- Home
- AQST vs APC Comparison
AQST vs APC Comparison
Compare AQST & APC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.95
Company Overview
Basic Information| Metric | AQST | APC |
|---|---|---|
| Founded | 2004 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil Refining/Marketing |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 819.0M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | AQST | APC |
|---|---|---|
| Price | $3.95 | $19.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.83 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 255.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,430,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.63 | N/A |
| P/E Ratio | ★ N/A | $25.80 |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.20 | $17.82 |
| 52 Week High | $7.55 | $19.50 |
Technical Indicators
Market Signals| Indicator | AQST | APC |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | N/A |
| Support Level | $3.72 | N/A |
| Resistance Level | $3.99 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 44.23 | 0.00 |
Price Performance
Historical Comparison AQST
APC
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.